Analysis

Analysis

Neumora's penny problem

Neumora received a Nasdaq minimum bid notice on Oct 26 and has until Apr 26, 2027. It held $116.8M cash at June 30 against $60M of debt.

NMRA

Investor Chat

Scorecard

NMRA
Investment Attractiveness: 4.1/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-04
Mixed
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-04
Mixed record
Investor Impact: 3/10, LimitedHow important this specific story was to investors when we published it, whether the news was good or bad. · Moderate evidence · As of 2026-11-02
LimitedModerate evidence

The biotech IR desk. Where money meets opportunities. Not investment advice.

Summary. Neumora Therapeutics (NMRA) said on October 30, 2026 that Nasdaq had notified it on October 26 that its shares had closed below $1.00 for too long. It has until April 26, 2027 to recover, and named a reverse stock split as one option. The notice follows the June failure of two Phase 3 depression trials of navacaprant, a 35% cut in staff and the loss of access to $45M of a K2 HealthVentures loan. Neumora had $116.8M of cash at June 30 and had borrowed $60M.

Neumora closed at about 37 cents on October 30. At that close of $0.367, its 187.9M shares were worth about $69M, well under its cash. A deficiency letter is a routine document. What it reveals about a company is not.

How it got here

On June 15 Neumora reported that KOASTAL-2 and KOASTAL-3, its Phase 3 studies of navacaprant in major depressive disorder, had missed their primary and key secondary endpoints. The numbers left little room for interpretation. In KOASTAL-2, depression scores fell 12.2 points on drug and 12.0 on placebo (p=0.813). In KOASTAL-3 placebo did slightly better, 10.8 against 10.1 (p=0.480). Even among the 426 patients enrolled after the company's early-2025 study changes, the two arms were level. Neumora stopped developing navacaprant.

The same 8-K announced a reduction in force of about 35%, which the company expects to save about $10M a year after about $2M of one-time costs. It said cash would last into the third quarter of 2027.

The loan

Days earlier, on June 10, Neumora had amended its loan with K2 HealthVentures. Interest-only payments now run to April 2029 and the loan matures on May 1, 2029. A minimum liquidity covenant took effect on July 1, set at 50% or 110% of the amount owed, or waived, depending on milestones and market value. The 10-Q states the facility is up to $125.0M, of which $60.0M is drawn and $20.0M is available at the lenders' discretion. The remaining $45.0M is tied to milestones that, in the company's words, "will not be met" now that navacaprant is discontinued. The rate is the greater of 10.45% or prime plus 2.95%.

Deals reviewed

  • June 10, 2026: Third amendment to the K2 HealthVentures term loan, extending interest-only to April 2029 and resetting the liquidity covenant. 8-K, 10-Q

The new management

In August the board made president Joshua Pinto chief executive and a director, and moved Paul Berns, the chief executive, to executive chair. The second-quarter release points the company at three programmes: NMRA-511 in Alzheimer's disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease, with data from the first two expected in the fourth quarter and second half of 2026.

Analysis: the case for caution

Our view is that a reverse split would cure the listing problem and none of the others.

First, the debt. Trading below cash looks like a margin of safety, until one nets off the $60M owed to K2. That leaves about $57M of June cash against a market value of about $69M at the October 30 close, so on that basis the market values the pipeline at little more than nothing. The liquidity covenant can require up to 110% of the loan to be held in cash, about $66M on today's borrowings, or more than half the June cash.

Second, runway. Second-quarter net loss was $43.1M. Guidance of cash into the third quarter of 2027 gives Neumora two or three readouts to show results before it needs money again, and its share price makes a fresh equity raise expensive.

Third, focus. The company has moved from a late-stage depression story to three earlier programmes in unrelated fields. That spreads a shrinking budget across psychiatry, neurology and metabolism.

In fairness, Neumora was quick to act. It stopped navacaprant within days, cut costs and reworked its loan before the covenant applied. The NMRA-511 and NMRA-898 readouts could change the picture.

What to watch

The NMRA-511 and NMRA-898 data, the third-quarter 10-Q and covenant status, and any reverse split proposal before April 26, 2027.

FAQ

Why did Neumora get a Nasdaq notice? Its closing bid stayed below $1.00, breaching Listing Rule 5450(a)(1), per the October 30 8-K.

What is the deadline? April 26, 2027, with a possible extension if it moves to the Nasdaq Capital Market.

How much cash and debt does Neumora have? $116.8M of cash at June 30, 2026 and $60.0M borrowed from K2, per the 10-Q.

Is this investment advice? No. This is analysis of public filings.

Sources: Neumora Therapeutics SEC filings and press releases as linked. Market value uses the October 30, 2026 close and the 10-Q cover share count. Not investment advice.

Sources

Every figure comes from the documents above. Chart values come from the company's financial statements as tagged in its SEC filings; derived values are labelled. If you find an error, tell us.

Disclosures

  1. Every figure carries the as-of date of its source.
  2. This analysis was drafted with AI tools from the company's own filings, FDA documents and trial registries. Every number is checked against its source and an editor reviews the piece before it is published.
  3. Our method and conflicts policy: aibio.space/disclosures/

aibio.space and its owner hold no position in any stock covered in this report.

As of , aibio.space has received no compensation from, and has no paid relationship with, the company covered.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.